Canada
· Delayed Price · Currency is CAD Lobe Sciences Statistics
Total Valuation
Lobe Sciences has a market cap or net worth of CAD 3.43 million. The enterprise value is 5.60 million.
| Market Cap | 3.43M |
| Enterprise Value | 5.60M |
Important Dates
The next estimated earnings date is Friday, December 20, 2024.
| Earnings Date | Dec 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lobe Sciences has 171.56 million shares outstanding. The number of shares has increased by 60.10% in one year.
| Shares Outstanding | 171.56M |
| Shares Change (YoY) | +60.10% |
| Shares Change (QoQ) | +100.63% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | n/a |
| Float | 82.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.44 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.89 |
| EV / Sales | 5.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29.26 |
Financial Efficiency
Return on equity (ROE) is -4,833.76% and return on invested capital (ROIC) is -134.32%.
| Return on Equity (ROE) | -4,833.76% |
| Return on Assets (ROA) | -62.09% |
| Return on Capital (ROIC) | -134.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 2.29 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 49.83 |
| Average Volume (20 Days) | 32,814 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lobe Sciences had revenue of CAD 976,739 and -2.97 million in losses. Loss per share was -0.02.
| Revenue | 976,739 |
| Gross Profit | 950,970 |
| Operating Income | -2.82M |
| Pretax Income | -2.76M |
| Net Income | -2.97M |
| EBITDA | -2.71M |
| EBIT | -2.82M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 40,992 in cash and 2.21 million in debt, giving a net cash position of -2.17 million or -0.01 per share.
| Cash & Cash Equivalents | 40,992 |
| Total Debt | 2.21M |
| Net Cash | -2.17M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.11M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.07M |
Cash Flow
| Operating Cash Flow | -1.07M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 97.36% |
| Operating Margin | -289.04% |
| Pretax Margin | -282.69% |
| Profit Margin | n/a |
| EBITDA Margin | -277.85% |
| EBIT Margin | -289.04% |
| FCF Margin | n/a |
Dividends & Yields
Lobe Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -60.10% |
| Shareholder Yield | -60.10% |
| Earnings Yield | -124.60% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on June 10, 2022. It was a reverse split with a ratio of 0.166666667.
| Last Split Date | Jun 10, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.166666667 |
Scores
Lobe Sciences has an Altman Z-Score of -31.01. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -31.01 |
| Piotroski F-Score | n/a |